Today, The FH Foundation, is pleased to recognize UnitedHealthcare for streamlining its prior authorization process and expanding access to PCSK9 inhibitors for familial hypercholesterolemia (FH). These changes are making it easier and faster for doctors and patients who qualify to get access to these important therapies.
UnitedHealthcare … VIEW ARTICLE
Katherine Wilemon, founder and CEO of the FH Foundation, talked with Daniel Levine of The Bio Report podcast, about familial hypercholesterolemia (FH). The episode highlights how FH is an invisible condition that causes high LDL-C cholesterol and increases the risk for early heart disease. Unfortunately, too may individuals … VIEW ARTICLE
The results of the ODYSSEY Outcomes trial of Alirocumab (Praluent) were presented today at the American College of Cardiology Scientific sessions. Alirocumab is an injectable antibody PCSK9 inhibitor that has been shown to significantly reduce LDL-cholesterol levels in prior trials.
ODYSSEY was … VIEW ARTICLE